A Phase I clinical trial to evaluate the safety and pharmacokinetics of SHR0302 base ointment at single dose and multiple dose in healthy adult subjects
Latest Information Update: 03 Mar 2020
At a glance
- Drugs Ivarmacitinib (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Reistone Biopharma
- 03 Feb 2020 Status changed from recruiting to completed.
- 18 Oct 2019 New trial record